Replies to post #395407 on Zeev's Turnips Patch-No Politics (ZEEV)

[marginnayan]

Briefing.com EYET

EYET Eyetech Pharma: Color on conference call (14.30 -0.33)

-Update- Following EYET's conference call, CSFB continues to believe Macugen has $1 bln in US sales potential. Firm's Wet A.M.D. market model is unchanged, and they believe positive top-line Lucentis data further validates the anti-VEGF approach as evolving standard of care in wet A.M.D., which should provide additional momentum to Macugen's launch. Firm believes that Macugen is on track to beat 2005 sales guidance of $135-$150 mln. Firm believes that EYET's current share price reflects the assumption that Lucentis is flawless on both safety and efficacy, yet firm thinks it is too early for this conclusion.